Based on the Bicycle Therapeutics Ltd stock forecast from 7 analysts, the average analyst target price for Bicycle Therapeutics Ltd is USD 38.00 over the next 12 months. Bicycle Therapeutics Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Bicycle Therapeutics Ltd is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, Bicycle Therapeutics Ltd’s stock price was USD 19.45. Bicycle Therapeutics Ltd’s stock price has changed by -4.66% over the past week, -14.35% over the past month and +29.75% over the last year.
No recent analyst target price found for Bicycle Therapeutics Ltd
No recent average analyst rating found for Bicycle Therapeutics Ltd
Company Overview Bicycle Therapeutics Ltd
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom. Address: Portway Building, Cambridge, United Kingdom, CB21 6GS Read Less
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) whic...Read More
Frequently Asked Questions About Bicycle Therapeutics Ltd (BCYC) Stock
Based on ratings from 7 analysts Bicycle Therapeutics Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 7 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on BCYC's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for BCYC is USD 38.00 over the next 12 months. The maximum analyst target price is USD 55 while the minimum anlayst target price is USD 28.
BCYC stock's Price/Earning ratio is 1,839.00.
The last closing price of BCYC's stock was USD 19.45.
The most recent market capitalization for BCYC is USD 1.41B.
Based on targets from 7 analysts, the average taret price for BCYC is projected at USD 38.00 over the next 12 months.
This means that BCYC's stock price may go up by +95.37% over the next 12 months.
We can't find any ETFs which contains Bicycle Therapeutics Ltd's stock.
As per our most recent records Bicycle Therapeutics Ltd has 284 Employees.
Bicycle Therapeutics Ltd's registered address is Portway Building, Cambridge, United Kingdom, CB21 6GS.
You can get more information about it from Bicycle Therapeutics Ltd's website at https://www.bicycletherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Bicycle Therapeutics Ltd (BCYC) Stock
Based on ratings from 7 analysts Bicycle Therapeutics Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 7 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on BCYC's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for BCYC is USD 38.00 over the next 12 months. The maximum analyst target price is USD 55 while the minimum anlayst target price is USD 28.
BCYC stock's Price/Earning ratio is 1,839.00.
The last closing price of BCYC's stock was USD 19.45.
The most recent market capitalization for BCYC is USD 1.41B.
Based on targets from 7 analysts, the average taret price for BCYC is projected at USD 38.00 over the next 12 months.
This means that BCYC's stock price may go up by +95.37% over the next 12 months.
We can't find any ETFs which contains Bicycle Therapeutics Ltd's stock.
As per our most recent records Bicycle Therapeutics Ltd has 284 Employees.
Bicycle Therapeutics Ltd's registered address is Portway Building, Cambridge, United Kingdom, CB21 6GS.
You can get more information about it from Bicycle Therapeutics Ltd's website at https://www.bicycletherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BCYC !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
